<DOC>
	<DOCNO>NCT00803738</DOCNO>
	<brief_summary>The objective study demonstrate comparable safety efficacy Terconazole Vaginal Suppositories , 80 mg ( Test Product ) Terconazole Vaginal Suppositories , 80 mg ( Reference Product ) treatment subject vulvovaginal candidiasis order establish bioequivalence .</brief_summary>
	<brief_title>Safety Equivalence Terconazole Vaginal Suppository ( Test Product ) Compared Reference Terconazole Vaginal Suppository Treatment Vulvovaginal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Terconazole</mesh_term>
	<criteria>Female least 18 year age Presented symptomatic vulvovaginitis consistent diagnosis moniliasis Willing able read sign IRB approve ICF , include agreement comply study requirement indicate protocol . History hypersensitivity allergy imidazole Female pregnant lactating Was menstruate expect onset menses treatment day Had evidence bacterial , viral protozoal infection Had history alcoholism , drug abuse , problem would likely make subject unreliable study Had condition use medication , opinion Investigator , might interfere conduct result study placed prospective subject increase risk Had participate investigational study within 30 day prior study enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Vulvovaginal Candidiasis</keyword>
	<keyword>Terconazole</keyword>
</DOC>